HC Wainwright Forecasts Krystal Biotech Q1 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Krystal Biotech in a research note issued to investors on Wednesday, February 18th. HC Wainwright analyst J. Pantginis anticipates that the company will earn $1.30 per share for the quarter. HC Wainwright has a “Buy” rating and a $310.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.

Other equities research analysts have also issued research reports about the stock. Jefferies Financial Group lifted their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday. The Goldman Sachs Group lifted their price objective on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Chardan Capital upped their target price on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research report on Wednesday. Citigroup raised their price target on Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, TD Cowen reissued a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Nine analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $307.22.

Krystal Biotech Stock Performance

Shares of KRYS opened at $283.29 on Thursday. The company has a market capitalization of $8.22 billion, a PE ratio of 41.36 and a beta of 0.49. The company’s 50 day moving average price is $264.84 and its 200 day moving average price is $208.40. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 12,500 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the sale, the chief accounting officer owned 19,318 shares of the company’s stock, valued at $5,257,200.52. The trade was a 39.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 13.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Greenline Wealth Management LLC acquired a new position in Krystal Biotech during the 4th quarter worth $34,000. Sound Income Strategies LLC increased its stake in shares of Krystal Biotech by 1,270.0% in the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after purchasing an additional 127 shares during the period. UMB Bank n.a. lifted its position in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the last quarter. Bessemer Group Inc. boosted its stake in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares during the period. Finally, Global Retirement Partners LLC boosted its stake in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after purchasing an additional 142 shares during the period. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 beat: Krystal reported $1.70 EPS (vs. $1.62 est.) and $107.1M in VYJUVEK Q4 revenue with 94% gross margin — evidence of profitable commercial traction and stronger net income. Read More.
• Positive Sentiment: Regulatory/designation wins: FDA granted RMAT for KB707 (advanced NSCLC) and Fast Track for KB111 (Hailey‑Hailey disease) — these expedite development and add optionality beyond VYJUVEK. Read More.
• Positive Sentiment: Commercial progress: Over ~660 U.S. reimbursements for VYJUVEK and growing uptake in Germany, France and Japan (90+ patients prescribed across those markets). The company reiterated expansion plans and a strong cash position (~$956M). Read More.
• Positive Sentiment: Analyst uplift: Chardan raised its price target to $323 and reiterated a Buy, adding upward analyst momentum and supporting valuation narratives. Read More.
• Neutral Sentiment: Conference materials and transcripts: The Q4 earnings call transcript, slide deck and investor webcast are available for detailed read‑throughs (helpful for assessing management commentary on growth drivers and expenses). Read More.
• Negative Sentiment: Mixed market reaction / share weakness: Multiple outlets reported KRYS shares slipped (>2%) despite the earnings beat — suggests profit‑taking and short‑term volatility after the print. Read More.
• Negative Sentiment: Reimbursement & launch timing risk in Europe: Pricing negotiations in Germany and France could push meaningful EU revenue later into 2H‑2026/2027, adding execution risk to international growth. Read More.
• Negative Sentiment: Expense / guidance transparency concerns: SG&A rose materially year‑over‑year and management provided non‑GAAP combined R&D+SG&A guidance that excludes stock‑based comp (company says it cannot reliably reconcile)—this can create uncertainty around forward GAAP profitability. Read More.
• Negative Sentiment: Insider selling: Data show material insider sales activity over recent months, which can weigh on investor sentiment even as institutions adjust positions. Read More.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.